The addition of anti-CD138 antibody to DM4 had no effect on efficacy (Fig. 6), however, the conjugated antibody indatuximab ravtansine 2 mg/kg and 4 mg/kg demonstrated anti-tumor activity as monotherapy. This evidence concerns the gene SDC1 and neoplasm.